Core Viewpoint - Weigao Blood Purification (603014.SH) plans to issue shares to acquire 100% equity of Weigao Puri from Weigao Co., Weihai Shengxi, and Weihai Ruiming, with the valuation and transaction price yet to be determined as the audit and assessment work is still ongoing [1] Group 1 - The acquisition will add pre-filled drug delivery systems and automatic safety drug delivery systems to the company's main business, expanding its product line into the pharmaceutical packaging sector [1] - Post-transaction, the company aims to leverage the technical accumulation and product layout of the target company to enhance its offerings in the pharmaceutical packaging field [1] - The collaboration is expected to synergize the company's hollow fiber filtration technology with the target company's extensive customer resources in biopharmaceuticals, enabling mutual empowerment in product technology reserves and sales channels for biopharmaceutical filter business [1]
威高血净(603014.SH)：拟购买威高普瑞100%股权